Agreement signed for Mictonorm® and Mictonet® with APOGEPHA Arzneimittel GmbH

Consilient Health are pleased to announce the signing of an exclusive licence, distribution and sales promotion agreement with APOGEPHA Arzneimittel GmbH, a Dresden based pharmaceutical company, for Mictonorm^® and Mictonet^® in the BeNeLux region. Consilient Health will once again work with its trusted partner in BeNeLux, Goodlife Pharma, to market and distribute Mictonorm^® and Mictonet^®.

CEO of Consilient Health, Ahmed Al-Derzi commented, “we are delighted to sign Mictonorm^® and Mictonet^® and to strengthen our urology portfolio whilst forming a new partnership with APOGEPHA who are specialists in Urology.”

“We are happy to have contracted Consilient Health and Goodlife as our new partner in BeNeLux as we are convinced that the experienced team will enable the Mictonorm^® and Mictonet^® product portfolio to flourish in the territory” commented Stefanie Mandel, Head of International Alliances at APOGEPHA.

Goodlife Pharma’s Frits Rooth remarked, “Doctors in Belgium have been prescribing Mictonorm^® for more than 10 years.  At Goodlife we are confident we can build and strengthen this position and later make best efforts to take Mictonorm^® to the Netherlands.  Goodlife is convinced that the long-term and strategic collaboration between Consilient Health, APOGEPHA and Goodlife will make an excellent contribution to the performance of our companies.”